From 1 December 2021 rosuvastatin will be fully funded, subject to Special Authority criteria, for people at increased risk of cardiovascular complications due to high cholesterol. In addition, Māori and Pacific peoples with raised CVD risk may access rosuvastatin as first-line treatment, and a waiver process is available to patients already self-funding the medicine.
In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.
Last year, cilazapril with hydrochlorothiazide was discontinued, and now cilazapril alone is no longer funded for new patients. Consultant cardiologist Chris Ellis discusses what to do when patients with hypertension run out of their supply of these medications
Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2
Read the HAH Bulletin to find out more.